Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609346 | 1.00 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL24909283 | 1.00 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL609610 | 1.00 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL30700601 | 1.00 | NR1H2 (0.48) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL17097458 | 0.90 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL17098157 | 0.90 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL17097460 | 0.90 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL17056975 | 0.90 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL10145613 | 0.86 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3JAK2 | |
| SCHEMBL609152 | 0.86 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021213353-A1 | AMIDE OR SULFONAMIDE DERIVATIVE AND USE THEREOF | 苏州恩华生物医药科技有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| US-9181279-B2 | Cyclic amine derivatives as EP4 receptor antagonists | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-11-10 | — | — | US | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| EP-2729445-B1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2015-10-21 | — | — | EP | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087626-A1 | CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | PTGER4, PTGER1, PTGER3 | NR1H2 445/4885CHRM2 342/4885CHRM1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.